HMTXF
HEMOSTEMIX INC by Hemostemix Inc (HMTXF)
$07
About HEMOSTEMIX INC by Hemostemix Inc (HMTXF)
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.
Details
Daily high
$0.07
Daily low
$0.07
Price at open
$0.07
52 Week High
$0.28
52 Week Low
$0.02
Market cap
10.3M
Dividend yield
0.00%
Volume
400
Avg. volume
7,111
P/E ratio
-4.06
HEMOSTEMIX INC by Hemostemix Inc News
Details
Daily high
$0.07
Daily low
$0.07
Price at open
$0.07
52 Week High
$0.28
52 Week Low
$0.02
Market cap
10.3M
Dividend yield
0.00%
Volume
400
Avg. volume
7,111
P/E ratio
-4.06